CN1883711A - 用于支持对患者成像的溶液和方法 - Google Patents
用于支持对患者成像的溶液和方法 Download PDFInfo
- Publication number
- CN1883711A CN1883711A CNA2006101055469A CN200610105546A CN1883711A CN 1883711 A CN1883711 A CN 1883711A CN A2006101055469 A CNA2006101055469 A CN A2006101055469A CN 200610105546 A CN200610105546 A CN 200610105546A CN 1883711 A CN1883711 A CN 1883711A
- Authority
- CN
- China
- Prior art keywords
- solution
- photographic means
- support
- oct
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000003384 imaging method Methods 0.000 title claims abstract description 13
- 239000000700 radioactive tracer Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 15
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 14
- 239000002872 contrast media Substances 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 11
- 238000002608 intravascular ultrasound Methods 0.000 claims description 10
- 238000012831 peritoneal equilibrium test Methods 0.000 claims description 9
- 238000012636 positron electron tomography Methods 0.000 claims description 9
- 238000012877 positron emission topography Methods 0.000 claims description 9
- 238000002583 angiography Methods 0.000 claims description 8
- 238000002591 computed tomography Methods 0.000 claims description 8
- 238000002601 radiography Methods 0.000 claims description 8
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 6
- 239000003637 basic solution Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000000392 somatic effect Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000012530 fluid Substances 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002961 echo contrast media Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 108010008908 FS 069 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 1
- JXMIBUGMYLQZGO-UHFFFAOYSA-N Iotroxic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)COCCOCCOCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I JXMIBUGMYLQZGO-UHFFFAOYSA-N 0.000 description 1
- 101100185402 Mus musculus Mug1 gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-JVVVGQRLSA-N acetic acid Chemical compound [11C](C)(=O)O QTBSBXVTEAMEQO-JVVVGQRLSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-BJUDXGSMSA-N ammonia-(13)N Chemical compound [13NH3] QGZKDVFQNNGYKY-BJUDXGSMSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000013155 cardiography Methods 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZPDFIIGFYAHNSK-UHFFFAOYSA-K gadobutrol Chemical compound [Gd+3].OCC(O)C(CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-UHFFFAOYSA-K 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960003182 iotrolan Drugs 0.000 description 1
- 229960000506 iotroxic acid Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002558 medical inspection Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/504—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of blood vessels, e.g. by angiography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/44—Constructional features of apparatus for radiation diagnosis
- A61B6/4417—Constructional features of apparatus for radiation diagnosis related to combined acquisition of different diagnostic modalities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
- A61B6/5247—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from an ionising-radiation diagnostic technique and a non-ionising radiation diagnostic technique, e.g. X-ray and ultrasound
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Vascular Medicine (AREA)
- Optics & Photonics (AREA)
- High Energy & Nuclear Physics (AREA)
- Dentistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Immunology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
为支持成像要对患者同时实施两种不同的照相方法。在每种照相方法中可以将支持液体，例如造影剂或者示踪物给入患者体内。本发明提出，在将两种支持液体输给患者之前将其在一种共用的液体内相互混合，也就是说，本发明提供一种溶液，它由无药物活性物质的基本溶液(24)、作为第一照相方法(14)支持溶液的第一部分溶液(20)和作为第二照相方法(16)支持溶液的第二部分溶液(22)组成。可以使用第一和第二照相方法的多种组合。必要时在该液体中可以存在第三部分溶液，用于同时实施三种照相方法。
Description
技术领域
本发明涉及一种用于支持采用至少两种照相方法对患者成像的溶液(液体)。本发明还涉及一种用于支持对患者成像的方法。
背景技术
在医学检查中，不同成像方法的相互组合日益增加。例如，US 6772001B2公开了一种X射线***与血管内超声波的组合(IVUS，详细说明例如参见EP 0885594 B1)。US 6263043 B1公开了MRI与X射线设备的组合。计算机断层造影术与PET的组合例如由US 5391877有所公开。计算机断层造影术与血管造影的X射线装置组合的第一台样机由西门子公司安装。
在大量的这种照相方法中使用支持液体。在X射线领域(体外MRI和血管内MRI、IVMRI方面)，将造影剂给入患者的血液内。在核医学(PET)方面使用所谓的示踪物。
如果照相方法有目的的组合要求给入两种不同的支持液体，则这些液体迄今为止彼此分开给入。例如分别在患者的右臂和左臂利用输注瓶进行输注。
发明内容
本发明的要解决的技术问题是，使照相方法的实施变得容易。
本发明基于这种认识：作为各自照相方法支持液体使用的不同部分溶液可以在共同与基本溶液混合下共同给入患者，因为它们在患者的血液内本来也要混合。
本发明可以在广泛的应用领域上使用。例如，第一照相方法可以包括血管造影术X射线照相、采用超声波的体外照射、计算机断层造影术、MRI、PET或者SPECT，而第二照相方法可以包括血管内超声波、光学相干断层造影术(OCT)或者血管内MRI。第一照相方法也可以是计算机断层造影术而第二照相方法可以包括PET、SPECT或者血管造影术X射线照相。此外，第一照相方法可以是血管内超声波而第二照相方法可以是光学相干断层造影术(OCT)。第一照相方法也可以是血管内超声波而第二照相方法是血管内MRI。第一照相方法也可以是MRI而第二照相方法是血管造影术X射线照相、PET、SPECT或者计算机断层造影术。
这一切仅是举例。本发明并不局限于所提到的方法，而是也可以在照相方法未来可能形成的组合上使用。
作为基本溶液合适地使用生理盐水，但该基本溶液也可以含有盐酸、氨基丁三醇、依地酸钙钠(Natriumcalciumedetat)和/或者水。
依据本发明的溶液自然也可以包括作为第三照相方法支持液体的第三部分溶液，其中，第一照相方法例如为血管造影术X射线照相，第二照相方法为血管内超声波而第三照相方法为光学相干断层造影术(OCT)。
也可以将第四和其它部分溶液包括在内。
依据本发明的溶液也可以包括其它部分溶液，它含有用于抑制对第一和/或者第二(和/或者需要时第三)部分溶液出现身体反应的药物。这些药物可以像现有技术中公知的那样，减少诸如***反应、休克和惊厥发作等这些可能出现的不良身体反应危险的药物。
溶液一般还包括分子的或者遗传的标记物和示踪物(例如用于识别动脉粥样硬化的ED-B纤维结合蛋白)。该溶液也可以包括纳粒子造影剂或者标记物，例如“Alphagammabeta3”。此外，该液体包括荧光标记物或造影剂。作为该溶液的部分溶液也可以考虑“靶剂”，它是诊断标记物，积聚在确定的器官和肿瘤内，例如恶性肿瘤生物标记物MUG-1。
例如可以为癌症患者制造不同靶剂的混合液，其中，例如一种靶剂积聚在肝上的主肿瘤内，而第二靶剂则积聚在脊柱内的转移性病灶内。
依据本发明的溶液优选作为液体装入储存容器内。该溶液也可以选择处于注射器内，其中，可以进行静脉或者动脉注射，或者也适用于口服或者直肠给入或者设计为吸入。该液体也可以处于喷射器或者例如诸如输注泵的输注装置内。
溶液的提供可以如现有技术中那样进行，为包装(储存容器或者注射器)配备条形码标记，并且在使用放射性药物时，容器可以包括例如像铅外壳这种辐射穿不透的防护罩。
按照依据本发明的方法，为支持成像已经为患者确定了至少两种不同的成像方法，利用其反映患者特征。选择第一和第二照相方法的参数，据此可以确定第一和第二照相方法支持液体的用量。将两种用量混合并将混合液体同时给入患者体内。接着利用两种成像方法成像，其中，两种方法同时或者至少时间接近进行，但无论如何要在同一过程(诊断或治疗)的范围内进行。
附图说明
现借助附图对本发明的优选实施方式进行说明。其中：
图1示意地示出依据本发明的溶液给入患者的情况。
具体实施方式
图1示意地示出患者10。现在的情况表明，如果同时实施两种不同成像方法的话，可以对患者10进行最佳的检查。围绕患者平躺的检查台12设置适用于实施两种成像方法的装置14和16，其中，这里示意地示出代表相应装置的方框。例如方框14表示用于实施患者心室的数字减法血管造影术的X射线装置，而方框16则表示用于实施心瓣膜多普勒超声心动描记术或者用于识别室隔膜缺陷的装置。
两种借助装置14和16表示的方法要求给入造影剂。典型的X射线造影剂为Omnipaque、Ultravist和Biliscopin(均来自Schering公司)。典型的超声波造影剂为Levovist、Echovist-200以及Echovist-300(均来自Schering公司)以及Optison、Echogen、Sonovue、Aerosomes、Imagent、NC100100、Quantison和Sonovist。
根据装置14和16的设置，例如得出30ml用量的X射线造影剂Omnipaque适合作为X射线造影剂，而作为超声波造影剂适用14ml的Echovist，其中，毫升与药效的溶液相关。将这两种溶液在输注瓶18内相互混合并在图1中作为带有不同阴影的球(“分子”)示出，30ml的Omnipaque采用附图符号20标注，14ml的Echovist采用附图符号22标注。输注瓶18此外包括6ml的药物辅助物质，例如采用附图符号24标注的生理盐水。
这样得到50ml的输注瓶，里面有X射线造影剂和超声波造影剂两种造影剂并且适用于直接给入患者10。即，在两种照相方法之一开始之前，溶液从输注瓶18给入患者10。只要患者的血管内含有足够多的溶液，就可以开始实际的检查。检查期间利用装置14和16同时进行反映患者特征的成像。因此，心室的数字减法血管造影术可以与心瓣膜的超声心动描记术同时或者时间接近地进行。因为两种活性物质同时存在，所以两个装置14和16之间可以快速交替或者同时使用。
如上面已经提到的那样，本发明并不局限于X射线成像与超声波成像的组合上。输注瓶内也可以有其它部分溶液。例如为使用计算机断层造影术可以使用Schering公司的Isovist240/-300或者Gastrografin，为无论是在体外的MRI还是血管内的MRI情况下使用MRI，可以使用Schering公司的Resovist和Gadovist或者也可以使用Magnevist。
为进行例如PET检查的核医学检查，可以使用下列造影剂或者示踪物：FDG(F18-脱氧葡萄糖)、6-[18F]荧光-L-DOPA、16alpha-[18F]荧光示踪物、[150]水、[13N]氨和[11C]醋酸盐。
本发明的优点在于，为在采用不同的成像方法检查时提高图像质量，特别是对比度性能，仅需在所要检查的体内***导管或通入路径。由此可以更佳的质量更加可靠和更加迅速地对患者进行诊断和治疗。
Claims (11)
1.一种用于采用至少两种不同的照相方法(14、16)支持对患者(10)成像的溶液，包括：
a)无药物活性物质的基本溶液(24)，
b)作为第一照相方法(14)支持溶液的第一部分溶液(20)和
c)作为第二照相方法(16)支持溶液的第二部分溶液(22)。
2.按权利要求1所述的溶液，其特征在于，
第一照像方法包括血管造影术X射线照相、采用超声波的体外检查、计算机断层造影术、MRI、PET或者SPECT，而第二照相方法包括血管内超声波、光学相干断层造影术(OCT)或者血管内MRI，或者
第一照相方法为计算机断层造影术，而第二照相方法包括PET、SPECT或者血管造影术X射线照相，或者
第一照相方法为血管内超声波，而第二照相方法为光学相干断层造影术(OCT)，或者
第一照相方法为血管内超声波，而第二照相方法为血管内MRI，或者
第一照相方法为MRI，而第二照相方法为血管造影术X射线照相、PET、SPECT或计算机断层造影术。
3.按权利要求1或2所述的溶液，其特征在于，所述基本溶液包含生理盐水、盐酸、氨基丁三醇、依地酸钙钠和/或水。
4.按权利要求1至3之一所述的溶液，其特征在于，支持液体为造影剂、标记物或者示踪物。
5.按上述权利要求之一所述的溶液，包括
d)作为第三照相方法支持液体的第三部分溶液。
6.按权利要求5所述的溶液，其特征在于，第一照相方法为血管造影术X射线照相，第二照相方法为血管内超声波，而第三照相方法为光学相干断层造影术(OCT)。
7.按上述权利要求之一所述的溶液，包括
e)作为第四照相方法支持液体的第四部分溶液。
8.按上述权利要求之一所述的溶液，包括
f)其它溶液，它含有用于抑制对第一和/或第二部分溶液出现身体反应的药物。
9.按上述权利要求之一所述的溶液，其特征在于，将该液体装入储存容器(18)内。
10.按上述权利要求之一所述的溶液，其特征在于，该溶液处于注射器、喷射器或者输注装置，优选输注泵内。
11.一种用于支持对患者成像的方法，包括以下步骤：
-确定至少两种不同的照相方法，利用其反映患者的特征，
-选择第一和第二照相方法的参数，
-定义第一和第二照相方法支持液体的用量，
-将两种用量混合并且将混合液体给入(图1)患者体内，
-利用两种照相方法(14、16)同时或者时间接近地成像。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005028882A DE102005028882A1 (de) | 2005-06-22 | 2005-06-22 | Lösung und Verfahren zum Unterstützen der Bildgebung an einem Patienten |
| DE102005028882.0 | 2005-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1883711A true CN1883711A (zh) | 2006-12-27 |
Family
ID=37544797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101055469A Pending CN1883711A (zh) | 2005-06-22 | 2006-06-22 | 用于支持对患者成像的溶液和方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20070009431A1 (zh) |
| CN (1) | CN1883711A (zh) |
| DE (1) | DE102005028882A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112294260A (zh) * | 2020-10-10 | 2021-02-02 | 浙江大学 | 一种磁兼容的光学脑功能成像方法与装置 |
| WO2021213522A1 (zh) * | 2020-04-24 | 2021-10-28 | 苏州医本生命科技有限公司 | 一种具有示踪功能的药物制剂及其输送*** |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009037708B4 (de) | 2009-08-17 | 2019-02-21 | Carl Zeiss Meditec Ag | Erzeugnis zur Verwendung in einem OCT-Verfahren und Intraokularlinse |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3529195A1 (de) * | 1985-08-14 | 1987-02-26 | Max Planck Gesellschaft | Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung |
| GB9020091D0 (en) * | 1990-09-14 | 1990-10-24 | Nycomed As | Contrast media |
| US6613306B1 (en) * | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US5325860A (en) * | 1991-11-08 | 1994-07-05 | Mayo Foundation For Medical Education And Research | Ultrasonic and interventional catheter and method |
| US5391877A (en) * | 1994-01-26 | 1995-02-21 | Marks; Michael A. | Combined imaging scanner |
| US6818199B1 (en) * | 1994-07-29 | 2004-11-16 | James F. Hainfeld | Media and methods for enhanced medical imaging |
| DE19740533B4 (de) * | 1997-09-15 | 2004-04-08 | Siemens Ag | Medizinische Untersuchungsanlage |
| US5980459A (en) * | 1998-03-31 | 1999-11-09 | General Electric Company | Ultrasound imaging using coded excitation on transmit and selective filtering of fundamental and (sub)harmonic signals on receive |
| US6797257B2 (en) * | 2001-06-26 | 2004-09-28 | The Board Of Trustees Of The University Of Illinois | Paramagnetic polymerized protein microspheres and methods of preparation thereof |
| ITMI20011706A1 (it) * | 2001-08-03 | 2003-02-03 | Bracco Imaging Spa | Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic |
| CA2459724C (en) * | 2001-09-04 | 2011-02-15 | Texas Tech University System | Multi-use multimodal imaging chelates |
| DE10203372A1 (de) * | 2002-01-29 | 2003-09-04 | Siemens Ag | Medizinisches Untersuchungs- und/oder Behandlungssystem |
| US7198777B2 (en) * | 2003-06-17 | 2007-04-03 | The Board Of Trustees Of The University Of Illinois | Optical contrast agents for optically modifying incident radiation |
| US20050053551A1 (en) * | 2003-09-08 | 2005-03-10 | Badiola Carlos M. | Use of a combination of gadolinium-based contrast media and iodinated contrast media as a contrast agent for X-ray based medical imaging procedures |
| US7894880B2 (en) * | 2003-10-23 | 2011-02-22 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement of renal extraction fraction using contrast enhanced computed tomography |
| US7419654B2 (en) * | 2004-10-08 | 2008-09-02 | Mrinal K. Dewanjee | Charge neutral complexes of paramagnetic metals as intracellular magnetic resonance imaging contrast agents |
| FR2900043B1 (fr) * | 2006-04-24 | 2008-07-04 | Commissariat Energie Atomique | Procede d'imagerie optique par fluorescence de tissus biologiques, notamment pour delimiter des regions d'interet des tissus a analyser par tomographie |
| US20110110858A1 (en) * | 2009-11-11 | 2011-05-12 | Omer Aras | Gold nanoparticle imaging agents and uses thereof |
-
2005
- 2005-06-22 DE DE102005028882A patent/DE102005028882A1/de not_active Ceased
-
2006
- 2006-06-22 US US11/472,881 patent/US20070009431A1/en not_active Abandoned
- 2006-06-22 CN CNA2006101055469A patent/CN1883711A/zh active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021213522A1 (zh) * | 2020-04-24 | 2021-10-28 | 苏州医本生命科技有限公司 | 一种具有示踪功能的药物制剂及其输送*** |
| CN112294260A (zh) * | 2020-10-10 | 2021-02-02 | 浙江大学 | 一种磁兼容的光学脑功能成像方法与装置 |
| CN112294260B (zh) * | 2020-10-10 | 2022-04-05 | 浙江大学 | 一种磁兼容的光学脑功能成像方法与装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE102005028882A1 (de) | 2007-01-04 |
| US20070009431A1 (en) | 2007-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5450847A (en) | Process for making doses formulation of contrast media from concentrate | |
| CN101951835B (zh) | 纳米级对比剂和使用方法 | |
| JP2014138860A (ja) | 放射性物質とともに使用するための輸注および移送システム | |
| EP2170405B1 (en) | Imaging diagnostics by combining contrast agents | |
| Balogh et al. | Veterinary Nuclear Medicine. Scintigraphical Methods-review | |
| CN1883711A (zh) | 用于支持对患者成像的溶液和方法 | |
| CN113423438A (zh) | 用于血管造影的改进方法 | |
| JP2007325945A (ja) | 大分子物質を生体の標的細胞に導入するシステム | |
| SI20148A (sl) | Priprava za projekcijsko mamografijo in postopek za uporabo te priprave | |
| Head et al. | Evaluation of the feline pancreas using computed tomography and radiolabeled leukocytes | |
| Thompson et al. | Diagnosis of a porto‐azygous shunt using helical computed tomography angiography | |
| Fischer | Occurrence of seizure during cranial computed tomography. | |
| Jeong et al. | Three-dimensional CT angiography of the canine hepatic vasculature | |
| CN111655298B (zh) | 包含氘代3-o-甲基葡萄糖用于肿瘤疾病磁共振的诊断制剂以及使用所述制剂的诊断方法 | |
| Hodges et al. | Lymphoscintigraphy in healthy dogs and dogs with experimentally created thoracic duct abnormalities | |
| US20130158388A1 (en) | Needle guidance for molecular imaging | |
| Chernov et al. | Phase I Trial of 99mTc-1-Thio-D-Glucose for Imaging of Lymphomas | |
| CN113546234B (zh) | 一种血管介入具有示踪功能的药物制剂及其输送*** | |
| CN118382404A (zh) | 一种示踪粒子及其应用和图像处理方法 | |
| EL-DESOUKI et al. | Uncommon Scintigraphic Findings of Muitiple Hepatic Hemangiomas | |
| US11090394B1 (en) | Modified nanodelivery system and method for enhanced in vivo medical and preclinical imaging | |
| Tarver et al. | The effect of contrast density on computed tomographic arterial portography | |
| Arnberg et al. | Selective intra-arterial administration of 18 F-FDG to the rat brain—effects on hemispheric uptake | |
| JP2020528048A (ja) | 用途依存ペイロード、制御された薬物動態学的分散、および腎クリアランスのための薬剤設計 | |
| Laitinen et al. | Novel technique of multislice CT angiography for diagnosis of portosystemic shunts in sedated dogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20061227 |